Adverse effect · Survodutide

How common is GI side effects with Survodutide?

B
Grade B — probable, not settledPhase 3 · effect size: large · adverse
Short answerProbable, not settled. Human data exist (Phase 3) and mostly agree, showing a large effect — but too few, too small, or not yet peer-reviewed for a firm answer. Mild-to-moderate gastrointestinal symptoms in 81% (3.6 mg) and 90% (6.0 mg) versus 48% on placebo in SYNCHRONIZE-1, with substantial discontinuation. SYNCHRONIZE-2: 72.8% and 77.7% versus 38.6%, generally mild to moderate and transient.

What the studies show

Mild-to-moderate gastrointestinal symptoms in 81% (3.6 mg) and 90% (6.0 mg) versus 48% on placebo in SYNCHRONIZE-1, with substantial discontinuation. SYNCHRONIZE-2: 72.8% and 77.7% versus 38.6%, generally mild to moderate and transient.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Survodutide in adults with obesity: SYNCHRONIZE-1, a randomised, double-blind, placebo-controlled phase 3 trial.N Engl J Med, published online 7 June 2026725 adults, 76 weeks, 3.6 mg and 6.0 mg versus placebo.
  2. 2
    Wharton S, et al. Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2).N Engl J Med, 2026 (online 1 Oct)752 adults, 76 weeks, 3.6 mg and 6.0 mg versus placebo. NCT06066528.

In context

Survodutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. In SYNCHRONIZE-1, a 725-person phase 3 trial published in June 2026, it produced 12–13% weight loss at 76 weeks against 5% on placebo, with gastrointestinal symptoms in up to 90% of participants. In people who also have type 2 diabetes the figure was 8–10% against 4% (SYNCHRONIZE-2, published October 2026). Its distinctive result is in the liver: a phase 2 trial resolved MASH without worsening fibrosis in 83% of patients at the top dose. It is not approved anywhere.

Survodutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Survodutide proven to cause GI side effects?
Not yet settled. Phase 3 — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Mild-to-moderate gastrointestinal symptoms in 81% (3.6 mg) and 90% (6.0 mg) versus 48% on placebo in SYNCHRONIZE-1, with substantial discontinuation. SYNCHRONIZE-2: 72.8% and 77.7% versus 38.6%, generally mild to moderate and transient.
Is Survodutide approved for this?
No. Survodutide is investigational; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Survodutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →